Flavonoids and animal health and production performance

By using naringin, naringin or a mixture thereof to target the regulation of bitter receptors and intestinal-brain axis receptors in animals, the problem of difficulty in improving animal feeding behavior and welfare in the prior art is solved, and the eating habits is achieved Significant effects of patterns and behaviors and improvements in animal welfare.

CN113453560BActive Publication Date: 2024-11-22HEALTHTECH BIO ACTIVES S L U
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080015650.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-02-21
Filing Date
2020-02-20
Publication Date
2024-11-22
Estimated Expiration
2040-02-20

AI Technical Summary

Technical Problem

The prior art is difficult to effectively improve feeding behavior and animal welfare in animals for a long time, and it is difficult to target specific gene receptors involved in the intestinal-brain axis, affecting the eating patterns and behaviors of animals.

Method used

Naringin, naringin, or a mixture thereof are used to target gene expression of bitter receptors and intestinal-brain axis receptors in ruminants and pigs, affecting the eating patterns and behaviors of animals.

Benefits of technology

It significantly changed the eating pattern of animals, reduced the size of full meals and fighting behavior, improved the health parameters of the rumen wall, and improved animal welfare.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003220974260000081
    Figure BDA0003220974260000081
  • Figure BDA0003220974260000201
    Figure BDA0003220974260000201
  • Figure BDA0003220974260000211
    Figure BDA0003220974260000211
Patent Text Reader

Abstract

The present invention relates to the use of naringin, its aglycone form naringenin or mixtures thereof for modulating the expression of certain specific gene receptors in ruminants and / or pigs, which has a positive effect on feeding behavior, intake patterns and animal behavior.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims the benefit of European Patent Application No. 19382127.9 filed on February 21, 2019. Technical Field

[0002] The present invention relates to the use of naringin, its aglycone form, naringenin or mixtures thereof for modulating the expression of certain specific gene receptors in ruminants and / or pigs, which has a positive effect on feeding behavior, intake patterns and animal behavior. Background Art

[0003] Phytochemicals are chemicals found in vegetables and edible fruits. They play an important role in plants, acting as protective molecules to protect plants from harmful agents (insects, bacteria) or stressful situations (UV, temperature, lack of water). In addition, phytochemicals show biological activities and health effects in humans and animals.

[0004] Flavonoids are well-studied polyphenols, and citrus fruits are considered the main source of flavonoids, containing many of these phytochemicals. Some of these compounds have anti-inflammatory, antioxidant and antimicrobial properties. Due to their interesting functions, flavonoids from different sources are being studied for different applications in animal production. CA (Interquim, SA, Spain) is an extract from bitter orange (Citrus aurantium), the main flavonoid of which is naringin. Naringin is a glycosylated flavanone classified as neohesperidin type, which has neohesperidose (rhamnosyl-α-1,2 glucose) attached to its basic structure as a flavanone. Other extracts containing naringin have shown beneficial effects in regulating the rumen pH of finishing beef cattle and reducing in vitro methane production from beef cattle fed a high concentrate diet. The properties of naringin may affect the rumen microbiota, thereby increasing the concentration of lactic acid-consuming bacteria such as Megasphaera elsdenii, thereby producing a higher rumen pH and inhibiting the methanogenic archaea community (PCT application number WO2013156574). Rumen volatile fatty acid (VFA) composition has also been altered, increasing the molar proportion of propionic acid. Because propionate is an important regulator of feed intake in ruminants fed a high-starch diet, affecting satiety and hunger, flavonoid supplementation may affect feeding patterns in bulls fed a high-concentrate diet. In addition, this supplementation may reduce methane production and, at the same time, reduce rumen pH fluctuations, which may increase nutrient utilization efficiency in young bulls.

[0005] However, the mechanism by which citrus flavonoids can modulate feeding and animal behavior is still unknown. Naringin is the flavonoid responsible for the typical bitter taste in some citrus fruits, so another possible mechanism may be related to bitterness, one of the five basic tastes (sweet, salty, bitter, sour and umami) that humans and animals can perceive. Recent studies have shown that taste receptors, including bitter taste receptors (TAS2R), are expressed in the gastrointestinal tract, including ruminants and pigs. Therefore, bitter taste receptors can modulate the feeding patterns of animals, thereby reducing meal size, improving digestive epithelial health parameters and thus increasing animal welfare. The nutritional gastrointestinal tract can have an impact on animal behavior, modulating sexual and aggressive behavior as well as oral non-nutritional behavior, because there is a connection between the digestive tract and the central nervous system, which is also called the gut-brain axis, in which digestive microorganisms are key players.

[0006] Several solutions have been proposed in the art so far in order to improve animal behavior and thus animal welfare. However, it is still difficult to obtain natural substances that have a long-term effect in animals, because the animals seem to get used to these substances and thus their positive effects disappear over time.

[0007] Therefore, there is a need in the art for new methods that can provide targeted modulation of gene expression of some specific gene receptors involved in the gut-brain axis, namely bitter taste receptors and immunity receptors, which positively influence feeding behavior, gastrointestinal microbiota, inflammatory responses and animal behavior.

[0008] Furthermore, it is an object of the present invention to provide an alternative animal feed composition comprising compounds of natural origin and which can be safely used in animal husbandry and which effectively improves feeding behavior and its effects on digestive disturbances, animal behavior and thus animal welfare.

[0009] In the present invention and specific embodiments thereof, the above problems have been solved. BRIEF DESCRIPTION OF THE DRAWINGS

[0010] Figure 1 Indicates whether feeding is supplemented or not supplemented Non-confrontational interactions of bulls on a high-concentrate diet in CA.

[0011] Figure 2 Indicates whether feeding is supplemented or not supplemented Antagonistic interactions of bulls fed a high-concentrate diet in CA.

[0012] Figure 3 Indicates whether feeding is supplemented or not supplemented Sexual interactions of bulls fed a high-concentrate diet in CA.

[0013] Figure 4Relative gene expression ratios in the rumen of Holstein bulls fed a high concentrate diet supplemented or not with Bioflavex CA after 168 days of treatment.

[0014] Figure 5 Relative gene expression ratio of TAS2R in the jejunum of piglets after 7 days of feeding with two diets corresponding to T1: basal diet and T2: T1 + bitter orange extract (300 g / Tm).

[0015] Figure 6 Relative gene expression ratios in the duodenum of Holstein bulls fed a high concentrate diet supplemented or not with Bioflavex CA after 168 days of treatment. Summary of the invention

[0016] In a first aspect, the present invention relates to a non-therapeutic method for targeted modulation of gene expression of at least one bitter taste receptor and / or at least one gut-brain axis receptor in ruminants and / or pigs, the method comprising administering naringin, naringenin or a mixture thereof.

[0017] In a second aspect, the present invention relates to naringin, naringenin or a mixture thereof for use in regulating gene expression of at least one immune-related gene in ruminants and / or pigs. DETAILED DESCRIPTION

[0018] The present invention relates to the use of naringin, its aglycone form naringenin or mixtures thereof for modulating the expression of certain specific gene receptors in ruminants and / or pigs, which has a positive effect on feeding behavior, intake patterns and animal behavior.

[0019] In a first aspect, the present invention relates to a non-therapeutic method for targeted modulation of gene expression of at least one bitter taste receptor and / or at least one gut-brain axis receptor in ruminants and / or pigs, the method comprising administering naringin, naringenin or a mixture thereof.

[0020] As used herein, the term "targeted modulation of gene expression" is meant to include reduction of gene expression as well as amplification of the gene expression.

[0021] The authors of the present invention have now discovered that administration of naringin, naringenin or a mixture thereof to ruminants and / or pigs significantly alters the expression of certain genes in the rumen epithelium of ruminants or in the intestine of pigs that are involved in taste perception, inflammation and gut-brain crosstalk mechanisms. This effect explains the observed differences in the feeding patterns and animal behavior of ruminants and / or pigs.

[0022] In addition, it was surprisingly found that ruminants supplemented with naringin, naringenin or a mixture thereof changed their eating patterns (reduced meal size and spent more time eating forage) and improved rumen wall health parameters. In addition, it was observed that ruminants supplemented with naringin, naringenin or a mixture thereof reduced aggression and sexual interaction.

[0023] Bitter taste receptors

[0024] In one embodiment of the present invention, the bitter taste receptor is selected from the group consisting of TAS2R7, TAS2R16, TAS2R38 and TAS2R39.

[0025] Taste receptors were originally found in taste buds located in different parts of the tongue and oral cavity. Recently, many studies have described taste receptors for the basic tastes (sweet, bitter, umami, sour and salty) present throughout the body, including the respiratory system and gastrointestinal tract. This peripheral taste system would have the following functions: taste the luminal contents of the digestive tract, and regulate the expression of nutrient transporters, the intake of nutrients, and also regulate the release of gastrointestinal hormones and neurotransmitters involved in regulating gastrointestinal function, food intake and satiety.

[0026] Bitter molecules trigger the release of anorectic hormones and peptides, such as cholecystokinin (CCK), neuropeptide Y (NPY), and peptide YY (PYY). This would be a logical reaction, as bitter taste is often associated with the presence of toxins and is considered to have a negative value. Therefore, the activation of an anorexygenic response in the digestive tract would be an adaptive response to this taste. Feeding and animal (social and sexual) behavior may be related. Several nutritional strategies have been described that focus on increasing feeding time and reducing aggression and abnormal behavior in animals.

[0027] The authors of the present invention found that during the video scanning process, bulls supplemented with naringenin, naringenin or a mixture thereof spent more time eating concentrate or ruminating. See, for example, the animal behaviors disclosed in Example 1 (Tables 7 and 8). Therefore, animals that spend more time on feeding activities have less time for other behaviors, such as aggressive behaviors and sexual interactions. At this time, bitter taste receptors in the digestive tract play an important role in regulating feeding behavior and animal behavior. In addition, surprisingly, the supplementation of flavonoids changed the rumen wall (as can be seen in Example 1 (Table 11)) and the duodenal epithelium (as can be seen in Example 3 (Table 12)). Figure 6) can be seen in the expression of genes for all bitter receptors (TAS2R7, TAS2R16, TAS2R38 and TAS2R39) analyzed. Although naringin has a unique bitter taste, it is rapidly deglycosylated to naringenin by enzymes, and rumen microflora can also degrade naringin to naringenin. In contrast to naringin, naringenin is an important bitter masking molecule, and this property is well known in the food industry, and it is mainly used in beverages (US 8,685,436). It has been described how some flavanones act as actual antagonists of the human bitter receptor TAS2R39, possibly reducing receptor responses by an orthosteric mechanism that acts on a single binding pocket of the bitter receptor. Example 1 and Example 3 show that the gene expression of the four bitter receptors (TAS2R7, TAS2R16, TAS2R38 and TAS2R39) analyzed in bulls supplemented with citrus flavonoids is reduced. These results are consistent with the function of naringenin as a bitter taste masking molecule and simultaneously as an antagonist of different bitter taste receptors. This reduction in gene expression of the analyzed bitter taste receptors may be related to feeding The results of the study suggest that citrus flavonoids may be associated with the longer eating time observed in bulls fed with citrus flavonoids. Therefore, supplementation with citrus flavonoids in bulls modulates eating patterns by regulating bitter taste receptors expressed in the rumen wall and duodenum, thereby altering the release of hormones and bioactive peptides involved in hunger and satiety. Therefore, citrus flavonoids may act as bitter-masking molecules in the rumen, and bulls supplemented with these flavonoids spend more time eating and show less agonistic and sexual interactions.

[0028] In the case of pigs, when citrus flavonoids were added to the feed of weaned piglets, gene expression of all analyzed bitter taste receptors (TAS2R7, TAS2R16, TAS2R38 and TAS2R39) was higher in the jejunum compared to non-supplemented animals, as shown from Example 2, Figure 5 It can be seen in.

[0029] As used herein, the term "flavonoid" refers to a class of water-soluble plant pigments that produce yellow or red / blue pigments in flower petals. The term "flavanone" refers to a flavonoid. Flavanones are typically glycosylated with a disaccharide at position seven to give "flavanone glycosides."

[0030] Gut-brain axis receptors

[0031] In another embodiment of the present invention, the gut-brain axis receptor is selected from the group consisting of FFAR2, FFAR3, PPYR1 and CCKBR.

[0032] The gut-brain axis has been proposed as a communication network between the digestive system and the brain, and may influence the behavior of humans and other animals. It has been suggested that the rumen may be involved in the crosstalk between the digestive system and the brain in beef cattle, and that altered aggressive and sexual behavior in animals may be related to this behavioral regulation. They observed that dietary changes in the expression of different genes (FFAR3, PPYR1, ADRA2C, occluding and TNFα) in the rumen of cattle fed a high concentrate diet may be involved in the gut-brain axis. These authors suggested that the rumen may play an important role in the crosstalk between the digestive system and the brain, and in altered aggressive and sexual behavior in animals. Surprisingly, the results of the present invention showed a significant decrease in the gene expression of receptors related to neurotransmitters, such as CCKBR (as CCK and gastrin receptor) and PPYR (as NPY and PYY receptor) in bulls supplemented with flavonoids, as shown in Example 1 (Table 11) and Example 3 ( Figure 6 These results are consistent with the reduced expression of bitter taste receptors analyzed in the rumen wall and duodenum of these animals, since these receptors are involved in the release of these anorectic molecules.

[0033] In another embodiment of the invention, the gene expression of at least one of said receptors is reduced. In a preferred embodiment of the invention, the gene expression of at least one of said receptors is reduced by at least 20%, preferably, by at least 30%, more preferably, by at least 40%.

[0034] As shown in the examples below, the inventors surprisingly found that by administering a feed composition according to the invention to ruminants, the expression of bitter taste receptors and gut-brain axis receptors was significantly reduced relative to those ruminants not fed such a composition.

[0035] As used herein, the term "ruminant" refers to any even-toed ungulate mammal of the suborder Ruminant. The mammal chews the cud and has a four-compartment stomach, one of which is the rumen. The group includes, in particular, cattle, buffalo, sheep, deer, camel, goat and antelope. The term "cattle" is understood to include cows, calves and bulls. In another embodiment of the invention, the ruminant of the first aspect is a cattle, buffalo, sheep, deer, camel, goat or antelope. In a preferred embodiment of the invention, the ruminant is a cattle.

[0036] As used herein, the term "pig" refers to any mammal of the Suidae family. The Suidae are sturdy animals with small eyes and coarse, sometimes sparse hair. All Suidae have a snout ending in a round cartilaginous disk for digging for food. Some species have tusks. Suidae are omnivorous and usually live in groups. The group includes pigs, wild or domestic pigs, meat pigs and boars in particular. In another embodiment of the present invention, the pig of the first aspect is a wild or domestic pig, meat pig or boar.

[0037] In another embodiment of the present invention, the amount of naringin, naringenin or a mixture thereof is administered as a mixture with a feed, wherein the feed composition comprises at least 0.005% w / w of naringin, or an equimolar amount of naringenin, or a mixture of naringin and naringenin in equimolar amounts if both are present.

[0038] In a preferred embodiment of the present invention, when the feed composition is administered to ruminants, the feed composition comprises at least 0.01% w / w of naringin, or an equimolar amount of naringenin, or a mixture of equimolar amounts of naringin and naringenin if both are present.

[0039] In another preferred embodiment of the present invention, when the feed composition is administered to pigs, the feed composition comprises at least 0.0075% w / w of naringin, or an equimolar amount of naringenin, or a mixture of equimolar amounts of naringin and naringenin if both are present.

[0040] Naringin is a flavanone-7-O-glycoside between the flavanone naringenin and the disaccharide neohesperidin. The flavonoid naringenin is naturally present in citrus fruits, especially in grapefruit, where naringenin is responsible for the bitter taste of the fruit. In commercial grapefruit juice production, naringinase can be used to remove the bitterness produced by naringin. In humans, naringin is metabolized to the aglycone naringenin (not bitter) by naringinase present in the intestine. Naringinase is a multi-enzyme complex with α-L-rhamnosidase and β-d-glucosidase active centers. This occurs in two steps, first, naringin is hydrolyzed into rhamnose and prunin by the α-L-rhamnosidase activity of naringinase. The formed prunin is then hydrolyzed into naringenin and glucose by the β-d-glucosidase activity of naringinase (see Scheme 1). Naringinase is an enzyme widely found in nature, and it is produced by many microorganisms (mainly fungi, yeasts and bacteria). Although glucosides can be cleaved by intestinal lactase-phlorizin hydrolase or intestinal epithelial cell β-glucosidase, there is no human α-L-rhamnosidase or rutinosidase, and the bioavailability of rhamnose containing flavonoids depends entirely on their cleavage by the intestinal flora. These enzymes can also be found in the intestine of pigs. However, in ruminants, they are in the rumen.

[0041]

[0042] Scheme 1. Hydrolysis of naringin by naringinase to give naringenin.

[0043] Naringenin has a flavanone backbone structure with three hydroxyl groups at carbons 4', 5, and 7. It can be found in aglycol form (naringenin) or in its glycoside form (naringin) with the addition of the disaccharide neohesperidose attached to carbon 7 via a glycosidic bond.

[0044] The equimolar amount of naringenin, or a mixture of naringin and naringenin, means, for example, that naringenin is equivalent to the amount of naringin in % w / w, taking into account the molecular weight. For example, 0.01% w / w of naringenin would be equivalent to 0.0053% w / w of naringenin.

[0045] In another preferred embodiment of the present invention, the feed composition is administered in the form of a paste or granules.

[0046] The feeding method is not limited to any specific feeding method, and the feed composition of the present invention may be administered by top application on top of a compound feed, or fed after the feed composition is mixed with a compound feed.

[0047] The shape of the feed composition according to the present invention is not limited to any specific shape, and may be any form of a conventional feed composition, such as a powder or paste and granules. In addition, the feed composition may be produced according to a method generally used for producing compound feeds and feed supplements.

[0048] The composition according to the invention may contain other feed ingredients, such as vitamins, enzymes, mineral salts, ground cereals, protein-containing components, carbohydrate-containing components, wheat middlings and / or bran meal.

[0049] The feed composition of the present invention can be any kind of animal feed, and its possible composition is well known to those skilled in the art, and is designed according to the nutritional requirements of specific animals and specific age periods. For example, piglet feed typically contains cereals, such as corn, wheat, soybeans, barley or oats; different protein sources, such as fish meal, soybean meal or animal plasma; amino acids, such as methionine, threonine, valine, tryptophan, arginine, histidine or leucine; and vitamins and minerals required for piglet growth (US National Research Council, NRC, 2012).

[0050] In another embodiment of the present invention, naringin, naringenin or a mixture thereof is administered at a daily dose of 0.001 to 0.01 g naringin per kg body weight of the animal, or an equimolar amount of naringenin, or an equimolar amount of a mixture of naringin and naringenin if both are present. In a preferred embodiment of the present invention, naringin, naringenin or a mixture thereof is administered at a daily dose of 0.002 to 0.003 g naringin per kg body weight of the animal, or an equimolar amount of naringenin, or an equimolar amount of a mixture of naringin and naringenin if both are present.

[0051] In another embodiment of the present invention, naringin, naringenin or a mixture thereof is in the form of a natural plant extract.

[0052] In another preferred embodiment of the present invention, the natural plant extract is bitter orange extract. In another preferred embodiment of the present invention, the bitter orange extract additionally comprises at least one flavanone glycoside selected from the group consisting of neohesperidin, isonaringin, citrus linalool, hesperidin and mixtures thereof.

[0053] In another preferred embodiment of the present invention, the bitter orange extract is a mixture comprising 20% ​​to 35% w / w naringin, 10% to 20% w / w neohesperidin and 0.5% to 5% w / w citrus glycosides, preferably, the bitter orange extract comprises 21% to 30% w / w naringin, 11% to 18% w / w neohesperidin and 1% to 5% w / w citrus glycosides, more preferably, the bitter orange extract comprises 25% to 27% w / w naringin, 11% to 15% w / w neohesperidin and 1% to 3% w / w citrus glycosides. In certain cases, the natural plant extract is commercially available

[0054] Therefore, according to the present invention, naringin, naringenin or a mixture thereof of the present invention can be obtained from plants, more specifically from citrus plants. All products according to the present invention are products of natural origin and are easily available.

[0055] As used herein, the term "citrus" refers to plants of the genus Citrus. Examples of the citrus plants include pomelo (Citrus maxima), citron (Citrus medica), mandarin orange (Citrus reticulata), bitter orange (Citrus aurantium), Persian lime (Citrus latifolia), lemon (Citrus limon), grapefruit (Citrus paradisi), sweet orange (Citrus sinensis), trifoliate orange (Citrus trifoliata), etc.

[0056] Methods for separating flavonoids from plants are well known in the prior art. In certain cases, bitter orange extracts can be obtained from ground citrus fruits (especially bitter orange) by general methods well known to those skilled in the art (e.g., extraction, filtration, concentration, precipitation, clarification and final drying). The extraction process can be carried out in a dibasic alkanol / water system, wherein the alkanol is selected from methanol, ethanol, propanol, etc. Methanol is preferably used. As an illustrative, non-limiting example, 50 g of dry bitter orange is extracted with 300 ml of methanol. The suspension is centrifuged to separate the residue, and the mother liquor is vacuum concentrated to a final volume of 50 ml. The resulting liquid is left to stand at room temperature for five days, filtered to separate insoluble matter, concentrated, filtered again through a diatomaceous earth bed and spray dried.

[0057] In a specific embodiment, the flavanone can be obtained from the fruit of citrus plants. For example, naringin is a glycosylated flavanone obtained from the peel of some lemon fruits (e.g., grapefruit and bitter orange). It is also found in the pulp of fruits and leaves, flowers and seeds of plants. Illustrative, non-limiting methods for separating flavonoids according to the present invention are those described, for example, in the documents US 2421063 A and US 2421062 A, which describe methods for recovering naringin from plant materials. In addition, hesperidin can be obtained according to the methods described in the documents US 2442110 A, US2348215 A and US 2400693 A. Similarly, neohesperidin can be obtained according to the methods described in the document US 3375242 A. US 3375242 A describes a method for producing neohesperidin, wherein naringin is reacted with isovanillin to produce neohesperidin chalcone. The chalcone is then cyclized to produce neohesperidin.

[0058] In addition, the flavonones of the composition of the present invention can be easily obtained because they are commercially available. For example, as shown in the examples accompanying the present invention, isonaringin, neoeritrocin and citrus glycosides were purchased from INDOFINE Chemical Company, Inc (USA). In addition, as mentioned above, the natural plant extracts according to the present invention are commercially available.

[0059] In another embodiment of the present invention, the bitter orange extract is administered at a daily dose of 0.005 g / kg to 0.02 g / kg of animal body weight, preferably the bitter orange extract is administered at a daily dose of 0.01 g / kg of animal body weight.

[0060] In another embodiment of the present invention, naringin, naringenin or a mixture thereof is administered to ruminants and / or pigs for at least 5 days. In a preferred embodiment of the present invention, naringin, naringenin or a mixture thereof is administered to pigs for at least 10 days. In another preferred embodiment, naringin, naringenin or a mixture thereof is administered to ruminants for at least 15 days.

[0061] Immune-related genes

[0062] In a second aspect, the present invention relates to naringin, naringenin or a mixture thereof for use in regulating gene expression of at least one immune-related gene in ruminants and / or pigs.

[0063] As used herein, the term "regulation of gene expression" is intended to include the reduction of gene expression and the amplification of the gene expression. It should also be understood that this regulation of gene expression can also lead to the regulation of the production of at least one immune-related gene in ruminants and / or pigs. Therefore, the reduction of gene expression of any immune-related gene will lead to the reduction of the gene production and further regulation of inflammation.

[0064] In addition, the authors of the present invention found that supplementation with citrus flavonoids significantly reduced the gene expression of receptors associated with inflammation in the rumen wall of bulls. Inflammation has been suggested to play an important role in animal welfare and behavior, possibly through gut-brain axis crosstalk. Inflammation may be involved in the reduction of serotonin levels in serum, due to increased use of the amino acid tryptophan for the production of kynurene. Serotonin is a neurotransmitter that plays an important role in the gut-brain axis and is associated with a reduction in mood regulation and aggressive behavior. In addition, selective serotonin reuptake inhibitors (which increase extracellular serotonin) are associated with decreased libido and sexual problems in humans. IL-25 is produced by a variety of cells, including immune and non-immune cells (epithelial and endothelial cells), and it can enhance allergic inflammation. Defensin-β is an antimicrobial peptide and has a regulatory effect on the innate and adaptive immune processes of mammals. Therefore, Example 1 (see Table 11) and Example 3 show that supplementation with citrus flavonoids reduces the gene expression of these pro-inflammatory molecules, and this may lead to a reduction in inflammatory responses and inflammation in the rumen wall and duodenum. Furthermore, naringenin, as a potent antioxidant, has anti-inflammatory effects consistent with the prior art. Furthermore, as listed in Tables 7 and 8, the results obtained indicate that bulls supplemented with citrus flavonoids showed a reduction in aggressive behavior and sexual interactions, and rumen gene expression data would support that a reduction in rumen inflammation may be a key contributor to this response.

[0065] In conclusion, concentrate intake regulation (timing of feeding) together with inflammation in the rumen wall and other gut-brain crosstalk mechanisms are involved in improving animal behavior and animal welfare with citrus flavonoid supplementation.

[0066] The term "animal welfare" as used herein includes three elements: the normal physiological functioning of the animal (which means, among other things, ensuring that the animal is healthy and well-nourished), its emotional state (including the absence of negative emotions such as pain and chronic fear), and its ability to express certain normal behaviors. Nevertheless, not all behaviors are equally important in terms of animal welfare. From a practical point of view, the clearest sign that a given behavior is important is whether the animal shows a stress response or exhibits abnormal behavior when prevented from performing that behavior. Pre-partum nesting behavior in sows or foraging behavior in pigs are examples of such important behaviors. These three principles are not necessarily contradictory; in fact, they are often complementary.

[0067] In one embodiment of the second aspect, the immune-related gene is selected from the group consisting of IL-6, IL-8, IL-10, IL-25 and β-defensin.

[0068] In another embodiment of the second aspect, the gene expression of at least one of said receptors is reduced. In a preferred embodiment of the invention, the gene expression of at least one of said receptors is reduced by at least 20%, preferably, by at least 30%, more preferably, by at least 40%.

[0069] As shown in the examples below, the present inventors surprisingly found that by administering a feed composition according to the present invention to ruminants, the expression of immune-related genes was significantly reduced relative to those ruminants not fed such a composition.

[0070] In another embodiment of the second aspect, the ruminant is cattle, buffalo, sheep, deer, camel, goat or antelope. In a preferred embodiment of the present invention, the ruminant is cattle.

[0071] In another embodiment of the second aspect, the pig is a wild boar or a domestic pig, a meat pig or a boar.

[0072] In another embodiment of the second aspect, the product is administered as a mixture with a feed, wherein the feed composition comprises at least 0.005% w / w naringin, or an equimolar amount of naringenin, or a mixture of equimolar amounts of naringin and naringenin if both are present. The product is meant to comprise naringin, naringenin, or a mixture thereof.

[0073] In a preferred embodiment of the second aspect, when the feed composition is administered to a ruminant, the feed composition comprises at least 0.01% w / w naringin, or an equimolar amount of naringenin, or a mixture of equimolar amounts of naringin and naringenin if both are present.

[0074] In another preferred embodiment of the second aspect, when the feed composition is administered to pigs, the feed composition comprises at least 0.0075% w / w naringin, or an equimolar amount of naringenin, or a mixture of equimolar amounts of naringin and naringenin if both are present.

[0075] In another preferred embodiment of the second aspect, the feed composition is administered in the form of a paste or granules.

[0076] In another embodiment of the second aspect, the product is administered at a daily dose of 0.001 to 0.01 g naringin per kg body weight of the animal, or an equimolar amount of naringenin, or a mixture of naringin and naringenin in equimolar amounts if both are present. In a preferred embodiment of the second aspect, the product is administered at a daily dose of 0.002 to 0.003 g naringin per kg body weight of the animal, or an equimolar amount of naringenin, or a mixture of naringin and naringenin in equimolar amounts if both are present.

[0077] In another embodiment of the second aspect, the product is in the form of a natural plant extract. In another preferred embodiment of the second aspect, the natural plant extract is a bitter orange extract. In another preferred embodiment, the bitter orange extract additionally comprises at least one flavanone glycoside selected from the group consisting of neohesperidin, isonaringin, citrus linalool, hesperidin, and mixtures thereof.

[0078] In another preferred embodiment of the second aspect, the bitter orange extract is a mixture comprising 20% ​​to 35% w / w naringin, 10% to 20% w / w neohesperidin and 0.5% to 5% w / w citrus glycosides, preferably, the bitter orange extract comprises 21% to 30% w / w naringin, 11% to 18% w / w neohesperidin and 1% to 5% w / w citrus glycosides, more preferably, the bitter orange extract comprises 25% to 27% w / w naringin, 11% to 15% w / w neohesperidin and 1% to 3% w / w citrus glycosides.

[0079] In another embodiment of the second aspect, the bitter orange extract is administered at a daily dose of 0.005 g / kg to 0.02 g / kg of animal body weight, preferably the bitter orange extract is administered at a daily dose of 0.01 g / kg of animal body weight.

[0080] In another embodiment of the second aspect, the product is administered to ruminants and / or pigs for at least 5 days. In a preferred embodiment of the second aspect, the product is administered to pigs for at least 10 days. In another preferred embodiment, the product is administered to ruminants for at least 15 days.

[0081] In a further embodiment of the second aspect, it relates to naringin, naringenin or a mixture thereof for use in treating or preventing diseases with inflammatory responses in ruminants and / or pigs.

[0082] The main inflammatory neurological diseases caused by bacteria in ruminants are: listeriosis, purulent leptomeningitis and meningoencephalitis, brain and spinal cord abscesses, basilar empyema, and neurotuberculosis.

[0083] Other aspects and embodiments of the invention are described in the following clauses:

[0084] Item 1.- A non-therapeutic method for targeted modulation of gene expression of at least one bitter taste receptor and / or at least one gut-brain axis receptor in ruminants and / or pigs, the method comprising administering naringin, naringenin or a mixture thereof.

[0085] Clause 2.- The method according to clause 1, wherein the bitter taste receptor is selected from the group consisting of: TAS2R7, TAS2R16, TAS2R38 and TAS2R39.

[0086] Clause 3.- The method according to clause 1, wherein the gut-brain axis receptor is selected from the group consisting of: FFAR2, FFAR3, PPYR1 and CCKBR.

[0087] Clause 4.- Method according to any of the preceding clauses, wherein the gene expression of said at least one of said receptors is reduced.

[0088] Clause 5.- Method according to any of the preceding clauses, wherein the gene expression of at least one of said receptors is reduced by at least 20%.

[0089] Clause 6.- Method according to any of the preceding clauses, wherein the gene expression of at least one of said receptors is reduced by at least 30%.

[0090] Clause 7.- Method according to any of the preceding clauses, wherein the gene expression of at least one of said receptors is reduced by at least 40%.

[0091] Clause 8.- The method according to any of the preceding clauses, wherein the ruminant is a cattle, buffalo, sheep, deer, camel, goat or antelope.

[0092] Clause 9.- The method according to any of the preceding clauses, wherein the ruminant is a cattle.

[0093] Clause 10.-Method according to any one of clauses 1 to 7, wherein the pig is a wild boar or a domestic pig, a meat pig or a boar.

[0094] Clause 11.- The method according to any of the preceding clauses, wherein said amount of naringin, naringenin or a mixture thereof is administered as a mixture with a feed, wherein said feed composition comprises at least 0.005% w / w of naringin, or an equimolar amount of naringenin, or a mixture of equimolar amounts of naringin and naringenin if both are present.

[0095] Clause 12.- The method according to the preceding clause, wherein when the feed composition is administered to a ruminant, said feed composition comprises at least 0.01% w / w of naringin, or an equimolar amount of naringenin, or a mixture of equimolar amounts of naringin and naringenin if both are present.

[0096] Clause 13.- The method according to clause 11, wherein when the feed composition is administered to pigs, the feed composition comprises at least 0.0075% w / w of naringin, or an equimolar amount of naringenin, or a mixture of equimolar amounts of naringin and naringenin if both are present.

[0097] Clause 14.-Method according to any one of clauses 11 to 13, wherein the feed composition is administered in the form of a paste or granules.

[0098] Clause 15.- The method according to any of the preceding clauses, wherein naringin or naringenin or a mixture thereof is administered at a daily dose of 0.001 to 0.01 g of naringin per kg of animal body weight, or an equimolar amount of naringenin, or an equimolar amount of a mixture of naringin and naringenin if both are present.

[0099] Clause 16.- The method according to any of the preceding clauses, wherein naringin or naringenin or a mixture thereof is administered at a daily dose of 0.002 to 0.003 g of naringin per kg of animal body weight, or an equimolar amount of naringenin, or an equimolar amount of a mixture of naringin and naringenin if both are present.

[0100] Clause 17.- The method according to any of the preceding clauses, wherein naringin, naringenin or a mixture thereof is in the form of a natural plant extract.

[0101] Clause 18.- The process according to the preceding clause, wherein said natural plant extract is bitter orange extract.

[0102] Clause 19.- The method according to the preceding clause, wherein the bitter orange extract additionally comprises at least one flavanone glycoside selected from the group consisting of neohesperidin, isonaringin, citrinin, hesperidin and mixtures thereof.

[0103] Clause 20.- The process according to any one of clauses 18 to 19, wherein the bitter orange extract is a mixture comprising 20% ​​to 35% w / w naringin, 10% to 20% w / w neohesperidin and 0.5% to 5% w / w citrus glycosides.

[0104] Clause 21.- The process according to any one of clauses 18 to 20, wherein the bitter orange extract comprises 21% to 30% w / w naringin, 11% to 18% w / w. neohesperidin and 1% to 5% w / w citrus glycosides.

[0105] Clause 22.- The process according to any one of clauses 18 to 21, wherein the bitter orange extract comprises 25% to 27% w / w naringin, 11% to 15% w / w neohesperidin and 1% to 3% w / w citrus glycosides.

[0106] Clause 23.- The method according to any one of clauses 18 to 22, wherein the bitter orange extract is administered at a daily dose of 0.005 g per kg of animal body weight to 0.02 g per kg of animal body weight.

[0107] Clause 24.- The method according to any one of clauses 18 to 23, wherein the bitter orange extract is administered at a daily dose of 0.01 g per kg of animal body weight.

[0108] Clause 25.- The method according to any of the preceding clauses, comprising administering naringin, naringenin or a mixture thereof to a ruminant and / or pig for at least 5 days.

[0109] Clause 26.- The method according to the preceding clause, which comprises administering naringin, naringenin or a mixture thereof to pigs for at least 10 days.

[0110] Clause 27.- The method according to Clause 25, comprising administering naringin, naringenin or a mixture thereof to the ruminant for at least 15 days.

[0111] Item 28.- Naringin, naringenin or a mixture thereof for use in regulating the gene expression of at least one immune-related gene in ruminants and / or pigs.

[0112] Clause 29.- The product for use according to the preceding clause, wherein the immune-related gene is chosen from the group consisting of IL-6, IL-8, IL-10, IL-25 and beta-defensins.

[0113] Item 30.-Product for use according to any one of items 28 to 29, wherein the gene expression of at least one of said receptors is reduced.

[0114] Item 31.-Product for use according to any one of items 28 to 30, wherein the gene expression of at least one of said receptors is reduced by at least 20%.

[0115] Item 32.-Product for use according to any one of items 28 to 31, wherein the gene expression of at least one of said receptors is reduced by at least 30%.

[0116] Item 33.-Product for use according to any one of items 28 to 32, wherein the gene expression of at least one of said receptors is reduced by at least 40%.

[0117] Item 34.- The product for use according to any one of items 28 to 33, wherein the ruminant is a cattle, buffalo, sheep, deer, camel, goat or antelope.

[0118] Clause 35.- The product for use according to any one of clauses 28 to 34, wherein the ruminant is a cattle.

[0119] Article 36.- The product for use according to any one of Articles 28 to 35, wherein the pig is a wild boar or a domestic pig, a meat pig or a boar.

[0120] Item 37.- The product for use according to any one of items 28 to 36, wherein the product is administered as a mixture with a feed, wherein the feed composition comprises at least 0.005% w / w of naringin, or an equimolar amount of naringenin, or a mixture of equimolar amounts of naringin and naringenin if both are present.

[0121] Clause 38.- The product for use according to the preceding clause, wherein when the feed composition is administered to a ruminant, the feed composition comprises at least 0.01% w / w of naringin, or an equimolar amount of naringenin, or a mixture of equimolar amounts of naringin and naringenin if both are present.

[0122] Item 39.- The product for use according to Item 37, wherein when the feed composition is administered to pigs, the feed composition comprises at least 0.0075% w / w of naringin, or an equimolar amount of naringenin, or a mixture of equimolar amounts of naringin and naringenin if both are present.

[0123] Item 40.- The product for use according to any one of items 37 to 39, wherein the feed composition is administered in the form of a paste or granules.

[0124] Item 41.- The product for use according to any one of items 28 to 40, wherein the product is administered at a daily dose of 0.001 to 0.01 g of naringin per kg of animal body weight, or an equimolar amount of naringenin, or a mixture of equimolar amounts of naringenin and naringenin if both are present.

[0125] Item 42.- The product for use according to any one of items 28 to 41, wherein the product is administered at a daily dose of 0.002 to 0.003 g of naringin per kg of animal body weight, or an equimolar amount of naringenin, or a mixture of equimolar amounts of naringenin and naringenin if both are present.

[0126] Clause 43.- The product for use according to any one of clauses 28 to 42, wherein the product is in the form of a natural plant extract.

[0127] Clause 44.-Product for use according to the preceding clause, in which the natural plant extract is bitter orange extract.

[0128] Clause 45.- The product for use according to the preceding clause, wherein the bitter orange extract additionally comprises at least one flavanone glycoside chosen from the group consisting of neohesperidin, isonaringin, citrus linalool, hesperidin and mixtures thereof.

[0129] Clause 46.- The product for use according to any one of clauses 44 to 45, wherein the bitter orange extract is a mixture comprising 20% ​​to 35% w / w naringin, 10% to 20% w / w neohesperidin and 0.5% to 5% w / w citrus glycosides.

[0130] Clause 47.- The product for use according to any one of clauses 44 to 46, wherein the bitter orange extract comprises 21% to 30% w / w naringin, 11% to 18% w / w neohesperidin and 1% to 5% w / w citrus glycosides.

[0131] Clause 48.- The product for use according to any one of clauses 44 to 47, wherein the bitter orange extract comprises 25% to 27% w / w naringin, 11% to 15% w / w neohesperidin and 1% to 3% w / w citrus glycosides.

[0132] Item 49.- The product for use according to any one of items 44 to 48, wherein the bitter orange extract is administered in a daily dose of 0.005 g per kg of animal body weight to 0.02 g per kg of animal body weight.

[0133] Item 50.- The product for use according to any one of items 44 to 49, wherein the bitter orange extract is administered at a daily dose of 0.01 g per kg of animal body weight.

[0134] Item 51.- The product for use according to any one of items 28 to 50, which comprises administering the product to a ruminant and / or a pig for at least 5 days.

[0135] Clause 52.- The product for use according to the preceding clause, which comprises administering the product to pigs for at least 10 days.

[0136] Item 53.- The product or composition for use according to Item 51, which comprises administering the product to the ruminant for at least 15 days.

[0137] Specific implementation plan

[0138] The present invention will now be described in more detail with reference to the following examples, which should in no way be construed as limiting the scope of the present invention.

[0139] Example 1: Effects of flavonoids on performance, animal behavior and rumen gene expression in bulls fed a high-concentrate diet

[0140] Materials and Methods

[0141] Animals, feeding, housing, and experimental design

[0142] This study was conducted in accordance with the Spanish guidelines for the protection of experimental animals (Royal Decree 53 / 2013 of February 1 on the protection of animals used for experimental or other scientific purposes; Spanish Official Bulletin (Boletín Oficial del Estado), 2013). 144 Holstein bulls (164.8 ± 5.91 kg body weight (BW) and 135 ± 7.2 days of age) were fattened under commercial conditions at a farm (Granja l'Alzina, L'Alzina, Lleida). Animals were randomly assigned to one of eight fully covered pens (12x6m) that were covered with hay and equipped with a vertical feeder (1.50m long, 0.40m wide, 1.50m high and 0.35m deep). The feeder in each pen weighed the concentrate continuously, and these data were recorded to calculate the concentrate consumption of the pen, as described by Verdú et al. (2017).

[0143] The pen was also equipped with a waterer (0.30 m long, 0.30 m wide, 0.18 m deep) and a water meter to record the daily water consumption of the pen. Forage was provided ad libitum in a separate forage feeder (3.60 m long, 1.10 m wide, 0.32 m deep), and each forage change was recorded to estimate total forage consumption. As forage was also used for bedding, these data are only estimates.

[0144] Feed consumption and performance

[0145] Animals were fed a commercial concentrate in the form of a diet, formulated to meet the nutritional requirements of the animals (NRC, 2001). During the first 112 days of the study, animals were fed a growing concentrate formula, and between 112 days and the end of the study, animals were fed a finishing concentrate. The ingredients and nutritional composition of the concentrates are shown in Table 1. Throughout the study, animals had ad libitum access to wheat grass (3.5% CP, 1.6% ether extract, 70.9% NDF and 6.1% ash; based on DM) and fresh water.

[0146] Table 1. Ingredients and nutrient composition of feed concentrates

[0147]

[0148]

[0149] DM: Dry Matter; UFc: Meat Forage Crop Units; CP: Crude Protein; NDF: Neutral Detergent Fiber; TDN: Total Digestible Nutrients; PDIE: Protein Digested Intestine (protein digested in the small intestine when rumen fermentable energy is limited)-Energy; PDIN: Protein Digested Intestine (protein digested in the small intestine when rumen fermentable nitrogen is limited)-Nitrogen; NFC: Non-Fiber Carbohydrates.

[0150] Animals were randomly assigned to one of eight pens and allocated to two treatments (control (C) or supplemented (BF) with 0.04% whole fruit enriched with >20% naringin ( One of the bitter orange extracts ( Citrus aurantium dulcis ) from Interquim, SA, Barcelona, ​​Spain) (4 pens per treatment).

[0151] Throughout the study, animals were weighed individually every 14 days in 12 experimental phases of 14 days, during the first 8 phases (from 1 to 112 days) animals consumed growth concentrate, and during the last 4 time periods (from 113 to 168 days) and during the days before slaughter, animals consumed finishing concentrate (see Table 1). After the 168-day study, bulls were transported to a slaughterhouse located 15 km from the farm (Escorxador del Grup Alimentari Guissona, Guissona, Spain). Animals were slaughtered within two weeks, 4 pens per week, two pens from C and two pens from BF bulls. The waiting time before slaughter was less than 6 h. Animals were weighed before loading. These animals were slaughtered in accordance with commercial practice and in compliance with EU Regulation 1099 / 2009 on the protection of animals at slaughter or slaughter. The warm carcass weight (HCW) of each animal was recorded.

[0152] Animal Behavior

[0153] Visual scanning procedures were performed on the 15th, 30th, 43rd, 57th, 71st, 85th, 94th, 112th, 127th, 141st, 155th, and 170th days of the study to study the general activity (standing, lying, eating, drinking, and rumination) and social behavior (non-confrontational, confrontational, and sexual interactions) of the animals in each pen. The recorded social behavior activities are described in Table 2. Visual observations were performed on both pens from 8:00 to 10:30 h am, as described by Mach et al. (2008), Rotger et al. (2006), Robles et al. (2007), and Martí et al. (2010). General activity was scored using 3 scanning samples of 10 s at 5 min intervals, and social behavior was scored during three consecutive sampling periods of 5 min. This scanning procedure was repeated twice in each pen for 15 min, starting randomly in different pen each scanning day. This method describes the behavior exhibited by animals at fixed time intervals.

[0154] Table 2. Description of the categories of social behavior recorded.

[0155]

[0156]

[0157] Carcass quality

[0158] After slaughter, the warm carcass weight (HCW) of each animal is registered. The dressing percentage is calculated by dividing the HCW by the body weight (BW) recorded before slaughter. The morphology of the carcasses is classified according to the (S)EUROP categories described in EU Regulations No. 1208 / 81 and No. 1026 / 91, where "E" corresponds to excellent morphology, "U" corresponds to very good morphology, "R" corresponds to good morphology, "O" corresponds to fair morphology, and "P" corresponds to poor morphology. Fat coverage is classified according to EU Regulation No. 1208 / 81, which utilizes a classification system numbered 1.2.3.4.5, where 5 indicates a very high degree of fat coverage and a large amount of fat deposits in the chest cavity, and 1 is classified as a low degree and no fat coverage.

[0159] Rumen and liver macroscopic assessment and sample collection

[0160] The rumen and liver of each animal were macroscopically assessed at the slaughterhouse. Rumens were classified from 1 to 5 based on visually assessed color, with "5" being black rumen and "1" being white rumen (González et al., 2001). They were also divided into regions according to Lesmeister et al. (2004) to examine the presence of ulcers, bald areas, and clustered papillae (Nocek et al., 1984). Liver abscesses were classified according to Brown et al. (1975).

[0161] In addition, 1-cm2 sections of each rumen site were sampled and rinsed twice with cold PBS after sampling and immediately incubated in RNA-later (Invitrogen, Madrid, Spain) to preserve RNA integrity. After incubation with RNA later at 4°C for 24 hours, the liquid was removed and the tissue was frozen at -80°C until further RNA extraction and subsequent gene expression analysis.

[0162] Biological and chemical analysis

[0163] 1-cm2 sections of each rumen site were sampled and rinsed twice with cold phosphate buffered saline (PBS) after sampling and immediately incubated in RNA-later (Invitrogen, Madrid, Spain) to preserve RNA integrity. After incubation with RNA later at 4°C for 24 hours, the liquid was removed and the tissue was frozen at -80°C until further RNA extraction and subsequent gene expression analysis.

[0164] During the study, concentrate samples were collected on days 0, 42, 84, 126, and 168 and analyzed for dry matter (DM) (24 h at 103°C), ash (4 h at 550°C); crude protein (CP) by the Kjeldahl method (Method 981.10; AOAC, 1995); acid detergent fiber (ADF) and neutral detergent fiber (NDF) according to Van Soest et al. (1991) using sodium sulfite and α-amylase; and ether extract (EE) by Soxhlet using previous acid hydrolysis (Method 920.39; AOAC, 1995).

[0165] Naringin was identified as the BF group in each sample. CA marker and was used as a quality control assay to ensure that the product was correctly added to the feed by Interquim SA's in-house method for naringin quantification (using HLPC developed by Interquim SA) (Paniagua et al., 2018).

[0166] For gene expression analysis, total RNA was extracted from rumen wall tissue using Trizol (Invitrogen). Isolated mRNA was reverse transcribed into cDNA using the PrimeScript RT kit (Takara, Frankfurt, Germany) following the manufacturer's instructions. RNA purity was assessed by NanoDrop instrument (ThermoFisher, Madrid, Spain) at 260, 280, and 230 nm. Quantification of the expression of genes encoding: 1) genes encoding the production, expression, and turnover of the following neurotransmitters: free fatty acid receptor 2 (FFAR2) and free fatty acid receptor 3 (FFAR3), pancreatic polypeptide receptor 1 (PPYR1); cholecystokinin B receptor (CCKBR), 2) genes encoding the proinflammatory cytokine or cytokine IL-25 (IL25) and the antimicrobial peptide β-defensin released by enterocytes, and 3) bitter taste receptor type 2 members 7, 16, 38 and 39 (TAS2R7, TAS2R16, TAS2R38 and TAS2R39) was performed by quantitative PCR (qPCR) using the gene encoding ribosomal protein subunit 9 (RPS9) as a housekeeping gene. The stability of this housekeeping gene was examined in comparison with genes encoding β-actin (ACTB), ubiquitously expressed transcript (UXT) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) following Vandesompele et al. (2002). qPCR conditions were optimized for each set of primers individually. The specificity of amplification was assessed by identification of a single band at the expected molecular weight in a 0.8% DNA agarose gel and a single peak in the melting curve. The efficiency was calculated by amplifying serial 1:10 dilutions of each gene amplicon. The standard curve of the intersection point (Cq) was plotted against the logarithm of the concentration to obtain the efficiency, which was calculated using the formula 10 1 / 斜率 Calculated, its acceptable range is 1.8 to 2.2. A total reaction volume of 20 μL was used, which contained 50 ng cDNA, 10 μL SYBR Premix EXTaq (TliRNAseH) (Takara, Frankfurt, Germany) and optimized primer concentrations for each gene. The qPCR reaction cycle was as follows: an initial denaturation step of 10 min at 95°C, followed by 40 cycles of 10 s at 95°C, 15 s at the optimized annealing temperature of each gene, 30 s at 72°C, and a final extension of 10 min at 72°C. Using the resulting Cq values, the relative expression of the selected genes was calculated by relative quantification using reference genes (housekeeping genes) and control group calibrators.

[0167] Ruminal volatile fatty acid (VFA) concentrations were analyzed using a CP-3800-GC (Varian, Inc., Walnut Creek, CA) using a semicapillary column composed of 100% polyethylene glycol esterified with nitroterephthalate (15 m×0.53 mm i.d., 0.5-μm film thickness, TRB-FFAP; Teknokroma, Barcelona, ​​Spain), bonded and cross-linked phase (method number 5560).

[0168] result

[0169] Animal Health

[0170] Two animals from the control group (Group C) were unable to complete the study due to lameness issues and were removed before Day 168. One animal in the CA treatment group (BF group or BF bull) that completed the study was also removed from the database due to long-term health problems. All data from these animals were removed from the database.

[0171] Intake and water consumption, production performance and carcass quality

[0172] Throughout the study, there were no statistical differences in concentrate intake between treatment groups (Table 3), either during the growing period (Table 4) or the finishing period (Table 5). Similarly, estimates of forage consumption did not show statistical differences throughout the study (Table 3), either during the growing period (Table 4) or the finishing period (Table 5). Throughout the study (Table 3), water consumption was not affected by treatment during either the growing period (Table 4) or the finishing period (Table 5).

[0173] Table 3. Feeding supplements Production performance, concentrate intake, and eating behavior of Holstein bulls fed a high-concentrate diet from 0 to 168 days of age in CA

[0174]

[0175] 1 Control = no supplementation, CA = Supplement 0.04% CA concentrate.

[0176] 2 T = treatment effect; Time = time effect (14-day period); T x Time = treatment x time interaction.

[0177] 3 ADG = average daily gain

[0178] 4 SEM = standard error of the mean for log-transformed data

[0179] Table 4. Feeding supplements Production performance, concentrate intake, and feeding behavior of Holstein bulls fed a high-concentrate diet from CA at 4 to 9 months of age

[0180]

[0181]

[0182] 1 Control = no supplementation, CA = Supplement 0.04% CA concentrate.

[0183] 2 T = treatment effect; Time = time effect (14-day period); T x Time = treatment x time interaction.

[0184] Table 5. Feeding supplements Production performance, concentrate intake, and feeding behavior of Holstein bulls fed a high-concentrate diet at CA between 9 and 11 months of age

[0185]

[0186] 1 Control = no supplementation, CA = Supplement 0.04% CA concentrate.

[0187] 2 T = treatment effect; Time = time effect (14-day period); T x Time = treatment x time interaction.

[0188] The average daily gain (ADG) during the growing period is shown in Table 4. No statistical differences were found in the analyzed production parameters during this period. However, during the finishing period, the ADG of BF bulls (1.41 ± 0.019 kg / d) was greater (P < 0.05) than that of the C group (1.36 ± 0.019 kg / d), and the CV of this parameter was less (P < 0.05) for the BF group (36.28 ± 1.831%) than for the C bulls (42.83 ± 1.831%) (Table 5). In addition, the CV of final BW was greater (P = 0.01) for BF bulls (8.24 ± 0.308%) than for C bulls (7.04 ± 0.308%). Feed conversion ratio (FCR) tended (P = 0.10) to be less for BF bulls (5.11 ± 0.108 kg / kg) than for C bulls (5.36 ± 0.108 kg / kg) at the end of the study, but BW (437.9 ± 1.85 kg) and concentrate intake (7.13 ± 0.126 kg / d) were not affected by treatment (Table 3). An interaction between treatment and time was found for FCR (P = 0.05) during the finishing period (Table 5).

[0189] In conclusion, during this finishing period, ADG was better for BF bulls without an increase in concentrate intake. Therefore, BF bulls were more efficient during this finishing period, despite only a numerical improvement in FCR. It was then hypothesized that bulls supplemented with flavonoids may have reduced satiety size, which could explain the improved concentrate efficiency during the finishing period and the greater ADG exhibited by these BF animals.

[0190] Carcass quality data are presented in Table 6. Final BW (451.51 ± 3.154 kg), dressing percentage (52.94% ± 0.326), carcass morphology and fat score were not affected by treatments.

[0191] Table 6. Feeding supplements Carcass quality of Holstein bulls fed a high concentrate diet in CA.

[0192]

[0193]

[0194] 1 Control = no supplementation, CA = Supplement 0.04% CA concentrate.

[0195] 2 T = treatment effect; Time = time effect (14-day period); T x Time = treatment x time interaction.

[0196] 3Carcass conformation: (S)EUROP categories as described in EU Regulations No 1208 / 81 and No 1026 / 91, where "E" corresponds to excellent conformation, "U" to very good conformation, "R" to good conformation, "O" to fair conformation, and "P" to poor conformation

[0197] Animal Behavior

[0198] All terms for animal behavior, general activity and active behavior during the growing and finishing periods are shown in Tables 7 and 8, respectively.

[0199] General activity. No statistical differences were found in the percentage of animals standing, lying, eating forage, and ruminating in each pen during the growing period (study days 0 to 112) throughout the visual observation period (2:30 h). The percentage of animals eating concentrate was greater in BF bulls compared with C animals (P < 0.01), and the proportion of animals drinking water during this growing period also tended to be greater (P < 0.10) in BF bulls than in C bulls.

[0200] For the finishing period, no differences were found in the proportion of animals standing, lying, eating forage, and drinking water per pen during the visual observation period. During the finishing period, the proportion of animals eating concentrate per pen tended to be greater (P < 0.10) in BF bulls than in C bulls, and the proportion of animals ruminating was greater (P < 0.01) in the BF group than in C bulls.

[0201] Active Behavior. During the growth period, the only parameter that was not affected by treatment during the visual scanning observation period was social behavior. Self-grooming behavior was greater in BF bulls than in the C group, and the C group displayed more oral non-nutritional behaviors than (P = 0.01) BF bulls. These results are shown graphically in Figure 1 All behaviors associated with confrontational interactions were statistically different during this growth period ( Figure 2 ), and C bulls displayed these behaviors more frequently. Fighting behavior was greater in C bulls than in BF bulls (P<0.01), and C bulls also showed more ramming than BF (P<0.01). C bulls showed more exclusion interactions than BF (P<0.01). Chasing and shooing interactions were occasionally observed, but were greater in C than in BF (P<0.05). C bulls showed more cleft-lip sniffing behaviors than BF (P=0.05). In addition, mount attempts and completed mounts tended to be greater in C bulls than in BF (P<0.10). Figure 3 ).

[0202] During the finishing period (113 to 168 days), no differences in social and oral behaviors were observed between treatments. Bulls in the C group tended (P < 0.10) to exhibit more self-grooming behaviors than BF bulls ( Figure 1). In addition, antagonistic behaviors, such as fighting and ramming interactions, were greater in the C group than in the BF group (P<0.001 and P<0.001, respectively). In addition, although ostracism and chasing were rare, C bulls showed more interactions than BF bulls (P<.0001 in both cases). Regarding sexual interactions, C bulls showed more mount attempts and completed mounts than BF bulls (P<0.001), and cleft-lip sniffing behaviors also tended to favor C bulls over BF bulls (P<0.10). The results of antagonism and sexual interactions are shown graphically in Figure 2 and 3 middle.

[0203] Table 7. Behavior, Days 1-112 of the Experiment (Study)

[0204]

[0205]

[0206] 1 C = control, BF = supplemented 0.04% CA concentrate

[0207] 2 T = treatment effect; Time = time effect (measurements were taken every 14 days); T x time = treatment x time interaction.

[0208] 3 SEM = standard error of the mean for log-transformed data (general activity) or root-transformed data (social behavior).

[0209] Table 8. Behavior, Days 112-168 of the Experiment (Study)

[0210]

[0211]

[0212] 1 C = control, BF = supplemented with 0.04% CA concentrate

[0213] 2 T = treatment effect; Time = time effect (measurements were taken every 14 days); T x time = treatment x time interaction.

[0214] 3 SEM = standard error of the mean for log-transformed data (general activity) or root-mean-square transformed data (social behavior).

[0215] When analyzing eating behavior, the visual observation period (morning) indicated that bulls supplemented with flavonoids had a greater occupancy rate of concentrate feeders compared to C bulls; this effect was more pronounced during the growing period than during the fattening period. Then, during the visual observation period, these BF animals spent more time concentrating on eating. During the growing period, despite the greater feeder occupancy rate, the concentrate intake of BF bulls was numerically smaller, indicating that the eating rate may be smaller. Although non-statistical differences in forage feeder occupancy were found throughout the study (morning visual scanning sampling data), BF bulls showed greater rumination behavior during the fattening period. These results are difficult to interpret, and this may be because the visual scanning program does not describe the total daily feeder occupancy rate and rumination activity. During the growing period, waterer occupancy tended to be greater in bulls supplemented with flavonoids. In general, dry matter intake is directly related to water intake.

[0216] Rumen fermentation

[0217] Rumen fermented VFAs are presented in Table 10. Total VFA concentrations in the rumen were not affected by treatment. The molar proportion of acetate was greater (P < .0001) in BF bulls than in C bulls, while the molar proportion of propionate was greater (P < .0001) in C bulls than in BF bulls. Thus, the acetate:propionate ratio was greater (P < .0001) in BF bulls than in C bulls. The remaining VFAs analyzed (butyrate, valerate, isobutyrate, and isovalerate) were not affected by treatment.

[0218] Table 10. Rumen fermentation parameters VFA of Holstein bulls fed a high concentrate diet supplemented or not with Bioflavex CA

[0219]

[0220] 1 Control = No supplementation

[0221] 2 BF CA = Supplement 0.04% CA concentrate.

[0222] Gene expression in the rumen

[0223] The relative expression ratios of the genes studied in the rumen epithelium are presented in Tables 11 and Figure 4 Flavonoid supplementation affected the relative expression ratios of all analyzed bitter taste receptors (TAS2Rs), with BF bulls expressing lower relative expression ratios than C bulls. The relative expression ratios of TAS2R7, TAS2R16, TAS2R38, and TAS2R38 in C bulls were greater (P = 0.002, P = 0.003, P = 0.002, and P = 0.002, respectively) than those in BF bulls.

[0224] The relative expression ratios of receptors related to neurotransmitter signaling were different in each receptor type. FFAR3 tended to be greater in C bulls than in BF bulls (P=0.10), while FFAR2 was greater in C bulls than in BF bulls (P=0.002). In addition, the relative expression ratios of PPYR1 and CCKBR were also greater in C bulls than in BF bulls (P=0.003 and P=0.007, respectively).

[0225] In addition, the relative expression ratios of inflammation-related receptors such as IL-25 and β-defensin were greater in C bulls than in BF bulls (P=0.005, P=0.03, and P=0.0002, respectively).

[0226] Table 11. Gene expression ratios of Holstein bulls fed a high concentrate diet supplemented or not with Bioflavex CA after 168 days of treatment

[0227]

[0228] 1 Control = no supplementation.

[0229] 2 BF CA = Supplement 0.04% CA concentrate.

[0230] 3 SEM was derived from statistical analysis of baseline 10 log-transformed data, and means were back-transformed values.

[0231] 4 Bitter taste receptor 7

[0232] 5 Bitter taste receptor 16

[0233] 6 Bitter taste receptor 38

[0234] 7 Bitter taste receptor 39

[0235] 8 Free fatty acid receptor 3 (GPR41)

[0236] 9 Free fatty acid receptor 2 (GPR43)

[0237] 10 Pancreatic polypeptide receptor 1

[0238] 11 Cholecystokinin receptor 4

[0239] Example 2: Effect of flavonoid supplementation of weaning diet on bitter taste receptors (T2R) in nursery period piglets The role of gene expression

[0240] Materials and Methods

[0241] Animals, feeding, housing, and experimental design

[0242] A total of 168 commercial crossbred piglets ([Large White x Landrace] x Pietrain pigs) were used in the experiment. Animals were obtained from the same commercial farm on the day of weaning and moved to a nursery (non-transportation). Male and female 21-d old piglets with a BW of 4-7 kg were used. Plastic ear tags with animal numbers were used for identification. For the production performance test, animals were distributed to 2 areas according to initial body weight. In each area, in order to balance the weight distribution, pigs were distributed in the pens. Each area therefore consisted of 6 pens of 14 animals, to which experimental diets were randomly assigned. Pigs were then distributed in 12 pens (14 piglets / pen / weaning batch). Each pen had a commercial uncovered hopper and nipple waterer to ensure ad libitum feeding and free access to water. Two experimental treatments (each treatment was repeated 6 times) were assigned to the pens.

[0243] Feeding plan

[0244] After weaning, the selected animals were provided with the same basal pre-starter diet following the same specifications, but supplemented or not with the experimental product under study. The pre-starter diet was fed ad libitum for fourteen consecutive days (Table 1 ingredients and Table 2 nutrient composition).

[0245] The experimental diets were produced in mash and packaged and labelled ready for dispatch to the farm. The diets were mixed in batches of 1500 kg.

[0246] Table 12. Composition of starter feed diet (%) 1

[0247]

[0248]

[0249] 1The following is supplied per kg of diet: 7,000 IU vitamin A (acetate); 500 IU vitamin D3 (cholecalciferol); 250 IU vitamin D (25-hydroxycholecalciferol); 45 mg vitamin E; 1 mg vitamin K3; 1.5 mg vitamin B1; 3.5 mg vitamin B2; 1.75 mg vitamin B6; 0.03 mg vitamin B12; 8.5 mg D-pantothenic acid; 22.5 mg niacin; 0.1 mg biotin; 0.75 mg folic acid; 20 mg Fe (amino acid chelate); 2.5 mg Cu (sulfate); 7.5 mg Cu (glycine chelate); 0.05 mg Co (sulfate); 40 mg Zn (oxide); 12.5 mg Zn (amino acid chelate); 12.5 mg of Mn (oxide); 7.5 of Mn (glycine chelate); 0.35 mg of I, 0.5 of Se (organic); 0.1 mg of Se (sodium).

[0250] Table 13. Nutrient composition of experimental starter feed diets (%, as feed basis)

[0251]

[0252]

[0253]

[0254] Treatment and experimental design

[0255] Two experimental treatments were prepared, control (T1) or supplemented (T2) with 0.03% whole fruit bitter orange extract (Citrus aurantifolia) enriched with >20% naringin ( CA, Interquim, SA, Barcelona, ​​Spain). Therefore, the different experimental treatments were as follows:

[0256] T1: Basic Diet

[0257] T2: T1 + bitter orange extract (300g / Tm)

[0258] Intestinal tissue sampling

[0259] One piglet from each pen was sacrificed on day 7 after weaning (recommended to be the most critical time period after weaning) and tissue samples from jejunal sections were collected in RNA later and formaldehyde, respectively, and preserved for further analysis.

[0260] Biological analysis

[0261] For gene expression analysis, total RNA was extracted from jejunal tissue using Trizol (Invitrogen). Isolated mRNA was reverse transcribed into cDNA using PrimeScript RT kit (Takara, Frankfurt, Germany) following the manufacturer's instructions. RNA purity was assessed at 260, 280, and 230 nm by NanoDrop instrument (ThermoFisher, Madrid, Spain). Quantification of the expression of genes encoding bitter taste receptor type 2 members 7, 17, 38 and 39 (TAS2R7, TAS2R16, TAS2R38 and TAS2R39) was performed by quantitative PCR (qPCR) using the gene encoding ribosomal protein subunit 9 (RPS9) as a housekeeping gene to examine the stability of this housekeeping gene compared to genes encoding β-actin (ACTB), ubiquitously expressed transcribed protein (UXT) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) following Vandesompele et al. (2002). qPCR conditions were optimized for each set of primers individually. The specificity of amplification was assessed by identification of a single band at the expected molecular weight in a 0.8% DNA agarose gel and a single peak in the melting curve. The efficiency was calculated by amplifying serial 1:10 dilutions of each gene amplicon. A standard curve of the intersection point (Cq) was plotted against the logarithm of the concentration to obtain the efficiency, which was calculated using the formula 10 1 / 斜率 Calculated, its acceptable range is 1.8 to 2.2. A total reaction volume of 20 μL was used, which contained 50 ng cDNA, 10 μL SYBR Premix EXTaq (TliRNAseH) (Takara, Frankfurt, Germany) and the optimized primer concentration for each gene. The qPCR reaction cycle was as follows: an initial denaturation step of 10 min at 95°C, followed by 40 cycles of 10 s at 95°C, 15 s at the optimized annealing temperature of each gene, 30 s at 72°C, and a final extension of 10 min at 72°C. Using the obtained Cq values, the relative expression of the selected genes was calculated by relative quantification using reference genes (housekeeping genes) and control group calibrators (Pfaffl, 2004, Eq. [3.5]).

[0262] result

[0263] The relative expression ratios of the studied genes in the piglet jejunal epithelium are presented in Figure 5 Flavonoid supplementation affected the relative expression ratios of all analyzed bitter taste receptors (TAS2R), with T2 piglets expressing greater relative expression ratios than T1 animals.

[0264] Example 3: Effects of flavonoids on duodenal epithelial gene expression in bulls fed a high-fat finishing diet

[0265] Materials and Methods

[0266] Same as Example 1

[0267] Feed consumption and production performance

[0268] Animals were fed a commercial concentrate in the form of a diet, formulated to meet the nutritional requirements of the animals (FEDNA, 2008). During the first 112 days of the study, animals were fed a growth concentrate formula, and between 112 days and the end of the study, animals were fed a high-fat finisher concentrate. The ingredients and nutritional composition of the concentrates are shown in Table 14. Throughout the study, animals had ad libitum access to wheat forage (3.5% CP, 1.6% ether extract, 70.9% NDF and 6.1% ash; based on DM) and fresh water.

[0269] Table 14. Ingredients and nutrient composition of feed concentrates

[0270]

[0271] 1 Days 0 to 112 of the study.

[0272] 2 113 days to the end of the study.

[0273] DM: dry matter; ME: metabolizable energy; CP: crude protein; NDF: neutral detergent fiber; NFC: non-fiber carbohydrates.

[0274] Animals were randomly assigned to one of eight pens and allocated to two treatments (control (C) or supplemented (BF) with 0.04% whole fruit enriched with >20% naringin ( One of the bitter orange extracts ( Citrus aurantium ) of Interquim, SA, Barcelona, ​​Spain) was used (4 pens per treatment).

[0275] Throughout the study, animals were weighed individually every 14 days in 12 experimental phases of 14 days, during the first 8 phases (from 1 to 112 days) the animals consumed a grower concentrate, and during the last 4 time periods (from 113 to 168 days) and during the days before slaughter, the animals consumed a finisher concentrate (see Table 14). After the 168-day study, the bulls were transported to a slaughterhouse located 15 km from the farm (Escorxador del Grup Alimentari Guissona, Guissona, Spain). The animals were slaughtered within two weeks, 4 pens per week, two pens from C and two pens from BF bulls. The waiting time before slaughter was less than 6 h. The animals were weighed before loading. The animals were slaughtered in accordance with commercial practice and in compliance with EU Regulation 1099 / 2009 on the protection of animals at slaughter or slaughter. The warm carcass weight (HCW) of each animal was recorded.

[0276] Biological and chemical analysis

[0277] 1-cm2 sections of each duodenal site were sampled and rinsed twice with cold phosphate buffered saline (PBS) after sampling and immediately incubated in RNA-later (Invitrogen, Madrid, Spain) to preserve RNA integrity. After incubation with RNA later at 4°C for 24 hours, the liquid was removed and the tissue was frozen at -80°C until further RNA extraction and subsequent gene expression analysis.

[0278] For gene expression analysis, total RNA was extracted from rumen wall tissue using Trizol (Invitrogen). Isolated mRNA was reverse transcribed into cDNA using the PrimeScript RT kit (Takara, Frankfurt, Germany) following the manufacturer's instructions. RNA purity was assessed by NanoDrop instrument (ThermoFisher, Madrid, Spain) at 260, 280, and 230 nm. Quantification of the expression of genes encoding: 1) genes encoding the production, expression, and turnover of the following neurotransmitters: free fatty acid receptor 2 (FFAR2) and free fatty acid receptor 3 (FFAR3), pancreatic polypeptide receptor 1 (PPYR1); cholecystokinin B receptor (CCKBR), 2) genes encoding the proinflammatory cytokine or cytokine IL-25 (IL25) and the antimicrobial peptide β-defensin released by enterocytes, and 3) bitter taste receptor type 2 members 7, 16, 38 and 39 (TAS2R7, TAS2R16, TAS2R38 and TAS2R39) was performed by quantitative PCR (qPCR) using the gene encoding ribosomal protein subunit 9 (RPS9) as a housekeeping gene. The stability of this housekeeping gene was examined in comparison with genes encoding β-actin (ACTB), ubiquitously expressed transcript (UXT) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) following Vandesompele et al. (2002). qPCR conditions were optimized for each set of primers individually. The specificity of amplification was assessed by identification of a single band at the expected molecular weight in a 0.8% DNA agarose gel and a single peak in the melting curve. The efficiency was calculated by amplifying serial 1:10 dilutions of each gene amplicon. The standard curve of the intersection point (Cq) was plotted against the logarithm of the concentration to obtain the efficiency, which was calculated using the formula 10 1 / 斜率 Calculated, its acceptable range is 1.8 to 2.2. A total reaction volume of 20 μL was used, which contained 50 ng cDNA, 10 μL SYBR Premix EXTaq (TliRNAseH) (Takara, Frankfurt, Germany) and optimized primer concentrations for each gene. The qPCR reaction cycle was as follows: an initial denaturation step of 10 min at 95°C, followed by 40 cycles of 10 s at 95°C, 15 s at the optimized annealing temperature of each gene, 30 s at 72°C, and a final extension of 10 min at 72°C. Using the resulting Cq values, the relative expression of the selected genes was calculated by relative quantification using reference genes (housekeeping genes) and control group calibrators.

[0279] result

[0280] Regarding the relative expression at the mRNA level of the genes studied in the duodenal epithelium, the data are presented in Figure 6 . Flavonoid supplementation affected the expression of all bitter receptors (TAS2R) analyzed except TAS2R38. In the duodenum, the relative expression of TAS2R7, TAS2R16, and TAS2R39 was greater in C bulls (P<0.001) than in BF bulls. The relative expression of some receptors related to neurotransmitter signaling was different in each treatment. FFAR2 was expressed in the C bulls (P<0.01) than in BF bulls. In addition, the relative expression of PPYR1 and CCKBR was also greater in C bulls than in BF bulls (P<0.01). In addition, the relative expression of the inflammation-related receptors IL-25 and β-defensins was also greater in C bulls than in BF bulls (P<0.05).

[0281] Gene expression of these pro-inflammatory molecules was reduced in the duodenal epithelium of BF bulls, as observed in the rumen epithelium in a previous study (Example 1). These results are also consistent with the reduction of studied nutrient-sensing receptors such as TAS2R, FFAR2, PPYR1, and CCKBR in the duodenal epithelium of BF bulls.

[0282] In conclusion, flavonoid supplementation altered to varying degrees the gene expression of genes in the duodenal epithelium that may be associated with the regulation of feeding patterns and animal behavior.

[0283] References

[0284] Brown, H., Bing, RF, Grueter, HP, McAskill, JW, Cooley, CO, Rathmacher, RP, 1975. Tylosin and chloretetracycline for the prevention of liverabscesses, improved weight gains and feed efficiency in feedlotcattle. J. Anim. Sci. 40, 207-213.

[0285] González, JM, Garcia de Jalón, JA, Askar, AR, Guada, JA, Ferrer, LM, de las Heras, M., 2001. Effect of the diet with barley protein core on ruminal pathology in lambs.

[0286] Lesmeister,KE,Tozer,PR,Heinrichs,a J.,2004.Development andanalysis of a rumen tissue sampling procedure.J.Dairy Sci.87,1336-1344.https: / / doi.org / 10.3168 / jds.S0022-0302(0302)X273.

[0287] Nocek,JE,Heald,CW,Polan,CE,1984.Influence of ration physicalform and nitrogen availability on ruminal morphology of growing bullcalves.J.Dairy Sci.67,334-343.https: / / doi.org / 10.3168 / jds.S00222-30238-838.

[0288] Mach,N.,Bach,A.,Realini,CE,Font and Furnols,M.,Velarde,A.,Devant,M.,2009.Burdizzo pre-pubertal castration effects on performance,behaviour,carcass characteristics,and meat quality of Holstein bulls fed high-concentrate diets.Meat. Sci.81,329-334.https: / / doi.org / 10.1016 / j.meatsci.2008.08.007.

[0289] Marti,S.,Velarde,A.,de la Torre,J.L.,Bach,A.,Aris,A.,Serrano,A.,Manteca,X.,Devant,M.,2010.Effects of ring castration with local anesthesiaand analgesia in Holstein calves at 3months of age on welfareindicators.J.Anim.Sci.88,2789-2796.https: / / doi.org / 10.2527 / jas.2009-2408.

[0290] Paniagua,M.,Crespo,J.,Bach,A.,Devant,M.,2018.Effects of flavonoidsextracted from Citrus aurantium on performance,eating and animal behavior,rumen health,and carcass quality in Holstein bulls fed high-concentratediets.Anim.Feed Sci.Technol.246,114-126

[0291] Robles,V.,González,L.A.,Ferret,A.,Manteca,X.,Calsamiglia,S.,2007.Effects of feeding frequency on intake,ruminal fermentation,and feedingbehavior in heifers fed high-concentrate diets.J.Anim.Sci.85,2538-2547.

[0292] Rotger,A.,Ferret,A.,Manteca,X.,Ruiz De La Torre,J.L.,Calsamiglia,S.,2006.Effects of dietary nonstructural carbohydrates and protein sources onfeeding behavior of tethered heifers fed high-concentratediets.J.Anim.Sci.84,1197-1204.

[0293] Vandesompele J,De Preter K,Pattyn F,Poppe B,Van Roy N,De Paepe A,Speleman F.Accurate normalization of real-time quantitative RT-PCR data bygeometric averaging of multiple internal control genes,Genome Biology,2002,vol.3 RESEARCH0034

[0294] Van Soest,P.J.,Robertson,J.B.,Lewis,B.A.,1991.Methods for dietaryfiber,neutral detergent fiber,and nonstarch polysaccharides in relation toanimal nutrition.J.Dairy Sci.74,3583-3597.https: / / doi.org / 10.3168 / jds.S0022-0302(91)78551-2.

[0295] Verdú,M.,Bach,A.,Devan,M.,2017.Effect of feeder design andconcentrate presentation form on performance,carcass characteristics,andbehavior of fattening Holstein bulls fed high-concentrate diets.Anim.FeedSci.Technol.

Claims

1. A non-therapeutic use of naringin, naringenin or a mixture thereof for targeted modulation of gene expression of at least one bitter taste receptor and / or at least one gut-brain axis receptor in ruminants to change feeding patterns and rumination, and / or for targeted modulation of gene expression of at least one bitter taste receptor in pigs to change feeding patterns, the non-therapeutic use comprising administering naringin, naringenin or a mixture thereof, wherein naringin, naringenin or a mixture thereof is administered as a mixture with feed, wherein the feed composition comprises at least 0.005% w / w of naringin, or an equimolar amount of naringenin, or a mixture of naringin and naringenin if both are present in equimolar amounts.

2. The non-therapeutic use according to claim 1, wherein the bitter taste receptor is selected from the group consisting of: TAS2R7, TAS2R16, TAS2R38 and TAS2R39.

3. The non-therapeutic use according to claim 1, wherein the gut-brain axis receptor is selected from the group consisting of: FFAR2, FFAR3, PPYR1 and CCKBR.

4. The non-therapeutic use according to claim 1, wherein the gene expression of at least one of the receptors is reduced.

5. The non-therapeutic use according to claim 1, wherein naringin or naringenin or a mixture thereof is administered at a daily dose of 0.001 to 0.01 g naringin per kg body weight of the animal, or an equimolar amount of naringenin, or an equimolar amount of a mixture of naringin and naringenin if both are present.

6. The non-therapeutic use according to claim 1, wherein naringin, naringenin or a mixture thereof is in the form of a natural plant extract.

7. The non-therapeutic use according to claim 6, wherein the natural plant extract is bitter orange extract.

8. The non-therapeutic use according to claim 7, wherein the natural plant extract is administered at a daily dose of 0.005 g per kg animal body weight to 0.02 g per kg animal body weight.

9. The non-therapeutic use according to any one of claims 1 to 8, comprising administering naringin, naringenin or a mixture thereof to ruminants and / or pigs for at least 5 days.

10. Non-therapeutic use of naringin, naringenin or a mixture thereof for modulating gene expression of at least one immune-related gene in ruminants and / or pigs, wherein the naringin, naringenin or a mixture thereof is administered as a mixture with a feed, wherein the feed composition comprises at least 0.005% w / w of naringin, or an equimolar amount of naringenin, or a mixture of naringin and naringenin if both are present in equimolar amounts.

11. The non-therapeutic use according to claim 10, wherein the immune-related gene is selected from the group consisting of IL-6, IL-8, IL-10, IL-25 and β-defensin.

12. The non-therapeutic use according to claim 10, wherein the gene expression of at least one immune-related gene is reduced.

13. The non-therapeutic use according to claim 10, wherein a daily dose of 0.001 to 0.01 g of naringin, or an equimolar amount of naringenin, or a mixture of equimolar amounts of naringin and naringenin if both are present, is administered per kg of animal body weight.

14. The non-therapeutic use according to any one of claims 10 to 13, comprising administering the naringin, naringenin or a mixture thereof to ruminants and / or pigs for at least 5 days.